Search results
Results from the WOW.Com Content Network
The Nottingham prognostic index (NPI) is used to determine prognosis following surgery for breast cancer. [1] [2] Its value is calculated using three pathological criteria: the size of the tumour; the number of involved lymph nodes; and the grade of the tumour. [1] It is calculated to select patients for adjuvant treatment.
For a physician, this score is helpful in deciding how aggressively to treat a condition. For example, a patient may have cancer with comorbid heart disease and diabetes. These comorbidities may be so severe that the costs and risks of cancer treatment would outweigh its short-term benefit.
A lifetime risk score of 7% means a woman's estimated risk of developing breast cancer through age 90 is 7%. Mammogram guidelines are for women at average risk, said Dr. Arif Kamal, chief patient ...
It assigns scores to individuals based on risk factors; a higher score reflects higher risk. The score reflects the level of risk in the presence of some risk factors (e.g. risk of mortality or disease in the presence of symptoms or genetic profile, risk financial loss considering credit and financial history, etc.).
Cancer slope factors (CSF) are used to estimate the risk of cancer associated with exposure to a carcinogenic or potentially carcinogenic substance. A slope factor is an upper bound, approximating a 95% confidence limit , on the increased cancer risk from a lifetime exposure to an agent by ingestion or inhalation .
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
MammaPrint is a prognostic and predictive diagnostic test for early stage breast cancer patients that assess the risk that a tumor will metastasize to other parts of the body. [1] It gives a binary result, high-risk or low-risk classification , and helps physicians determine whether or not a patient will benefit from chemotherapy .
The Liver Imaging Reporting and Data System (aka LI-RADS) is a quality assurance tool created and trademarked by the American College of Radiology in 2011 to standardize the reporting and data collection of CT and MR imaging patients at risk for hepatocellular carcinoma (HCC), or primary cancer of the liver cells. [1]